DiaMedica Therapeutics Statistics
Total Valuation
DMAC has a market cap or net worth of $345.93 million. The enterprise value is $286.28 million.
Important Dates
The next estimated earnings date is Tuesday, May 12, 2026, after market close.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DMAC has 53.88 million shares outstanding. The number of shares has increased by 16.28% in one year.
| Current Share Class | 53.88M |
| Shares Outstanding | 53.88M |
| Shares Change (YoY) | +16.28% |
| Shares Change (QoQ) | +5.62% |
| Owned by Insiders (%) | 47.24% |
| Owned by Institutions (%) | 24.45% |
| Float | 28.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 6.15 |
| P/TBV Ratio | 6.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.81, with a Debt / Equity ratio of 0.00.
| Current Ratio | 11.81 |
| Quick Ratio | 11.72 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -67.68% and return on invested capital (ROIC) is -44.14%.
| Return on Equity (ROE) | -67.68% |
| Return on Assets (ROA) | -39.92% |
| Return on Invested Capital (ROIC) | -44.14% |
| Return on Capital Employed (ROCE) | -61.16% |
| Weighted Average Cost of Capital (WACC) | 10.58% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.17M |
| Employee Count | 28 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, DMAC has paid $28,000 in taxes.
| Income Tax | 28,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +69.39% in the last 52 weeks. The beta is 1.15, so DMAC's price volatility has been higher than the market average.
| Beta (5Y) | 1.15 |
| 52-Week Price Change | +69.39% |
| 50-Day Moving Average | 7.83 |
| 200-Day Moving Average | 6.76 |
| Relative Strength Index (RSI) | 31.66 |
| Average Volume (20 Days) | 240,687 |
Short Selling Information
The latest short interest is 4.43 million, so 8.21% of the outstanding shares have been sold short.
| Short Interest | 4.43M |
| Short Previous Month | 4.15M |
| Short % of Shares Out | 8.21% |
| Short % of Float | 15.57% |
| Short Ratio (days to cover) | 23.32 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -34.40M |
| Pretax Income | -32.74M |
| Net Income | -32.77M |
| EBITDA | -34.35M |
| EBIT | -34.40M |
| Earnings Per Share (EPS) | -$0.70 |
Full Income StatementBalance Sheet
The company has $59.89 million in cash and $240,000 in debt, with a net cash position of $59.65 million or $1.11 per share.
| Cash & Cash Equivalents | 59.89M |
| Total Debt | 240,000 |
| Net Cash | 59.65M |
| Net Cash Per Share | $1.11 |
| Equity (Book Value) | 56.11M |
| Book Value Per Share | 1.04 |
| Working Capital | 55.50M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$29.06 million and capital expenditures -$40,000, giving a free cash flow of -$29.10 million.
| Operating Cash Flow | -29.06M |
| Capital Expenditures | -40,000 |
| Depreciation & Amortization | 43,000 |
| Net Borrowing | -10,000 |
| Free Cash Flow | -29.10M |
| FCF Per Share | -$0.54 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DMAC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.28% |
| Shareholder Yield | -16.28% |
| Earnings Yield | -9.47% |
| FCF Yield | -8.41% |
Analyst Forecast
The average price target for DMAC is $15.50, which is 141.43% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.50 |
| Price Target Difference | 141.43% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -14.63% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 15, 2018. It was a reverse split with a ratio of 1:20.
| Last Split Date | Nov 15, 2018 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
